Clinical Trial Update: Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC) [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence and food-effect evaluation of a Saxa/Dapa dual fixed-dose combination (saxagliptin + dapagliflozin) in type 2 diabetes mellitus; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapa (Dapagliflozin)
• Saxa (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED